3 hours Kronos Bio (NASDAQ:KRON) Receives “Overweight” Rating from Piper Sandler MarketBeat
Piper Sandler restated an “overweight” rating and set a $6.00 price objective on shares of Kronos Bio in a report on Tuesday.
Piper Sandler restated an “overweight” rating and set a $6.00 price objective on shares of Kronos Bio in a report on Tuesday.